Therapy satisfaction and adherence in patients with relapsing-remitting multiple sclerosis: The THEPA-MS survey

Therapeutic Advances in Neurological Disorders

Volumn 9, Issue 4, 2016, Pages 250-263

  Haase, Rocco ^a   Kullmann, Jennifer S ^b   Ziemssen, Tjalf ^c  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b A Sanofi Company   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

convenience; multiple sclerosis; patient adherence; patient satisfaction; patient centred outcomes research; quality of life; side effects; treatment effectiveness

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE;

ADULT; CLINICAL PRACTICE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EXPANDED DISABILITY STATUS SCALE; FATIGUE; FEMALE; FLU LIKE SYNDROME; GERMANY; HEADACHE; HUMAN; INJECTION SITE PAIN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT SATISFACTION; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; SKIN MANIFESTATION; TREATMENT DURATION;

EID: 84975726282     PISSN: 17562856     EISSN: 17562864     Source Type: Journal    
DOI: 10.1177/1756285616634247     Document Type: Review

References (45)

1. Agashivala N., Wu N., Abouzaid S., Wu Y., Kim E., Boulanger L., et al. (2013) Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study. BMC Neurol 13: 138.
2. Albrecht G., Hoogstraten J., (1998) Satisfaction as a determinant of compliance. Community Dent Oral Epidemiol 26: 139-146.
3. Atkinson M., Kumar R., Cappelleri J., Hass S., (2005) Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM Version II) among outpatient pharmacy consumers. Value Health 8 (Suppl. 1): S9-S24.
4. Atkinson M., Sinha A., Hass S., Colman S., Kumar R., Brod M., et al. (2004) Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2: 12.
5. Barbosa C., Balp M., Kulich K., Germain N., Rofail D., (2012) A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence. Patient Prefer Adherence 6: 39-48.
6. Boeru G., Milanov I., De Robertis F., Kozubski W., Lang M., Rojas-Farreras S., et al. (2013) Extaviject(R) 30g device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study. Med Devices (Auckl) 6: 175-184.
7. Brandes D., Callender T., Lathi E., O'Leary S., (2009) A review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse events. Curr Med Res Opin 25: 77-92.
8. Calkwood J., Cree B., Crayton H., Kantor D., Steingo B., Barbato L., et al. (2014) Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial. BMC Neurol 14: 220.
9. Chrystyn H., Small M., Milligan G., Higgins V., Gil E., Estruch J., (2014) Impact of patients' satisfaction with their inhalers on treatment compliance and health status in COPD. Respir Med 108: 358-365.
10. Clanet M., Wolinsky J., Ashton R., Hartung H., Reingold S., (2014) Risk evaluation and monitoring in multiple sclerosis therapeutics. Mult Scler 20: 1306-1311.
11. Claxton A., Cramer J., Pierce C., (2001) A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23: 1296-1310.
12. Compston A., Coles A., (2008) Multiple sclerosis. Lancet 372: 1502-1517.
13. Coons S., Gwaltney C., Hays R., Lundy J., Sloan J., Revicki D., et al. (2009) Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO good research practices task force report. Value Health 12: 419-429.
14. Costello K., Kennedy P., Scanzillo J., (2008) Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term. Medscape J Med 10: 225.
15. Delgado-Rodriguez M., Llorca J., (2004) Bias. J Epidemiol Community Health 58: 635-641.
16. Devonshire V., Lapierre Y., Macdonell R., Ramo-Tello C., Patti F., Fontoura P., et al. (2011) The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 18: 69-77.
17. DGN/KKNMS (2012). German Neurological Society (DGN). Leitlinie Zur Diagnose Und Therapie Der Ms [ Guidelines for MS Diagnosis and Treatment ].
18. Giovannoni G., Southam E., Waubant E., (2012) Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence. Mult Scler 18: 932-946.
19. Halpern R., Agarwal S., Dembek C., Borton L., Lopez-Bresnahan M., (2011) Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis. Patient Prefer Adherence 5: 73-84.
20. Hansen K., Schussel K., Kieble M., Werning J., Schulz M., Friis R., et al. (2015) Adherence to disease modifying drugs among patients with multiple sclerosis in Germany: a retrospective cohort study. PLoS One 10: e0133279.
21. Hanson K., Agashivala N., Stringer S., Balantac Z., Brandes D., (2013) A cross-sectional survey of patient satisfaction and subjective experiences of treatment with fingolimod. Patient Prefer Adherence 7: 309-318.
22. Hirji I., Gupta S., Goren A., Chirovsky D., Moadel A., Olavarria E., et al. (2013) Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient's perspective. Health Qual Life Outcomes 11: 167.
23. Ho P., Bryson C., Rumsfeld J., (2009) Medication adherence. Circulation 119: 3028-3035.
24. Horne R., (2006) Compliance, adherence, and concordance: implications for asthma treatment. Chest 130: 65S-72S.
25. Kass G., (1980) An exploratory technique for investigating large quantities of categorical data. J R Stat Soc Series C 29: 119-127.
26. Kern S., Reichmann H., Ziemssen T., (2008) [ Adherence to neurologic treatment. Lessons from multiple sclerosis. ]. Nervenarzt 79: 877-878, 880-872, 884-876 passim.
27. Kurtzke J, (1983) Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 33: 1444-1452.
28. Kurtzke J., (2000) Natural history and clinical outcome measures for multiple sclerosis studies. why at the present time does EDSS scale remain a preferred outcome measure to evaluate disease evolution? Neurol Sci 21: 339-341.
29. Lindhiem O., Bennett C., Trentacosta C., McLear C., (2014) Client preferences affect treatment satisfaction, completion, and clinical outcome: a meta-analysis. Clin Psychol Rev 34: 506-517.
30. Loh W., (2014) Fifty years of classification and regression trees. Int Stat Rev 82: 329-348.
31. Menzin J., Caon C., Nichols C., White L., Friedman M., Pill M., (2013) Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis. J Manag Care Pharm 19: S24-S40.
32. Osterberg L., Blaschke T., (2005) Adherence to medication. N Engl J Med 353: 487-497.
33. Polman C., Reingold S., Edan G., Filippi M., Hartung H., Kappos L., et al. (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald criteria'. Ann Neurol 58: 840-846.
34. Rieckmann P., Boyko A., Centonze D., Elovaara I., Giovannoni G., Havrdova E., et al. (2015) Achieving patient engagement in multiple sclerosis: a perspective from the multiple sclerosis in the 21st Century Steering Group. Mult Scler Relat Disord 4: 202-218.
35. Rothwell P., McDowell Z., Wong C., Dorman P., (1997) Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis. BMJ 314: 1580-1583.
36. Saiz A., Mora S., Blanco J., (2015) Therapeutic compliance of first line disease-modifying therapies in patients with multiple sclerosis. Compliance study. Neurologia 30: 214-222.
37. Steinberg S., Faris R., Chang C., Chan A., Tankersley M., (2010) Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clin Drug Investig 30: 89-100.
38. Treadaway K., Cutter G., Salter A., Lynch S., Simsarian J., Corboy J., et al. (2009) Factors that influence adherence with disease-modifying therapy in MS. J Neurol 256: 568-576.
39. Turk-Adawi K., Oldridge N., Tarima S., Stason W., Shepard D., (2013) Cardiac rehabilitation patient and organizational factors: what keeps patients in programs? J Am Heart Assoc 2: e000418.
40. Twork S., Nippert I., Scherer P., Haas J., Pohlau D., Kugler J., (2007) Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population. Curr Med Res Opin 23: 1209-1215.
41. US Department of Health and Human Services FDA Center for Drug Evaluation and Research (2006) Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 4: 79.
42. Van Onzenoort H., Menger F., Neef C., Verberk W., Kroon A., De Leeuw P., et al. (2011) Participation in a clinical trial enhances adherence and persistence to treatment: a retrospective cohort study. Hypertension 58: 573-578.
43. Vermersch P., Czlonkowska A., Grimaldi L., Confavreux C., Comi G., Kappos L., et al. (2014) Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler 20: 705-716.
44. Vrijens B., Vincze G., Kristanto P., Urquhart J., Burnier M., (2008) Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 336: 1114-1117.
45. Wong W., Chow Y., Chen P., Wong S., Fielding R., (2015) A longitudinal analysis on pain treatment satisfaction among Chinese patients with chronic pain: predictors and association with medical adherence, disability, and quality of life. Qual Life Res 24: 2087-2097.